glp 1 drugs and blindness Research shows GLP-1 are effective but complex GLP-1 RA Drugs May Be

Novo and Lilly will also want to show theyre pressing wealthy nations to pay closer to US rates for prescription drugs, which could placate Trump in the near term

If the reward-regulation hypothesis strengthens, GLP-1 agonists could become one of the most important neuro-metabolic drug classes of the next decade

Zhang Q, Delessa CT, Augustin R et al (2021) The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling

Merck and others are developing GLP-1s (MK-8521, orforglipron licensing, etc.), but as of 2026 none have announced capacity builds because their products are not yet commercial

Both follow similar timelines

However, this relationship diminished considerably after additional adjustments for these demographic factors [6]